Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target

Figure 3

Sequential combination of DAC and IDA efficiently inhibits tumor growth in subcutaneous AML mouse model. A, Outlines of the animal experiment protocol. B, Effect of DAC sequentially combining with IDA on tumor volume in a subcutaneous AML mouse model transplanted with U937 cells. Tumor volume is expressed as Mean ± SD. (n = 4). Statistical differences between groups were analyzed with one-way ANOVA, and statistical significance was defined as p < 0.05. (*) indicates statistically significant differences between the combined group and the control group. C, 18F-FDG micro PET image of subcutaneous AML mouse model treated with FBS, DAC alone, IDA alone and DAC followed by IDA. The white arrows point to the area of the subcutaneous AML tumor. The SUV of control group was 8.25, DAC group was 6.32, IDA group was 7.09, and DAC combining with IDA group was 4.77.

Back to article page